They will support the establishment of testing pathways for cancer and rare diseases, help enable clinicians to request genomic tests, introduce new models of care that support early access to genomic testing and understand where there are areas of unmet need. The NHS GMS is a key vehicle on the journey towards embedding personalised medicine into mainstream healthcare including, for example, targeted cancer treatments based on the DNA of a tumour instead of its location in the body and treatments guided by pharmacogenomic testing.
The GMS Alliances will continue this mission and help ensure this personalised approach becomes the norm for patients in the NHS in the future. Ensuring NHS staff have the understanding and confidence to utilise genomics safely and effectively is another key focus of the GMS Alliances. This will involve the development of Workforce Transformation programmes that cover nursing and midwifery, pharmacy and medicine with each NHS GMS Alliance being responsible for overseeing these programmes in their area.
This will all be made possible by facilitating strong collaborations across large geographies, by bringing together the Genomic Laboratory Hubs that form the backbone of the NHS GMS together with our clinical genetic services inclusive of genomic counsellors, with all provider organisations across the care continiuum and with Primary Care Networks, Cancer Alliances, research and academia and patients and public representatives to build trust in genomics, and provide clinical and scientific leadership to enable all staff across the NHS to use genomics safely, effectively and efficiently.
Patients will be at the heart of everything the NHS GMS Alliances will be doing, with representatives being present on their partnership and leadership boards and playing a key role in decision-making across each region and nationally through coordination with NHS England and NHS Improvement. F: Cookies are pieces of information stored on your computer in simple text files which our server can read and record. These files do not contain any sensitive information.
By continuing to browse our site, you agree to the use of cookies. Read more about how GMS uses cookies. Will whole genome sequencing WGS be available? WGS will be part of the new genomic medicine service but we will not be offering this clinically until sometime in autumn Initially, it will be available for 21 rare disease indications and four cancers ALL, AML, paediatric cancer and sarcoma. We are in the process of mapping all of these pathways in our geography and will be in touch with relevant healthcare professionals over the coming weeks to give more detail and show you the new ordering system: National Genomic Information Service NGIS.
This system may ultimately be used for ordering all genomic tests, but the rollout will be gradual and will start with those tests going to WGS. The staged rollout will allow us to deliver training gradually to all who need it in a strategic way. Research in the new Genomic Medicine Service. As part of the new GMS there will be a national data repository or data library developed. All patients having genomic testing will be asked to choose whether or not to allow their data and any excess samples to be stored and available for research, and whether they are happy to be contacted about research opportunities in the future.
0コメント